Power Law company profile

Puma Biotechnology

Biotech & Life Sciences · Los Angeles, United States · Founded 2010 · IPO 2012 Thoroughbred

Biotechnology company that acquires and develops innovative products for the treatment of various forms of cancer

Valuation

$313M

Market cap · May/2026

Revenue

$228M

Latest reported FY

EBITDA

$53M

Latest reported FY

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

5 investors on Puma Biotechnology's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 5 investors entered at this stage

Foresite Capital

Tekla Capital Management

Bain Capital

OrbiMed

Jennison Associates

Global footprint

Where Puma Biotechnology has talent and traffic

Workforce by country

5 countries with
team presence

🇺🇸 United States97.4%

🇺🇦 Ukraine0.6%

🇪🇸 Spain0.6%

🇦🇿 Azerbaijan0.6%

🇦🇺 Australia0.6%

5 countries shown

Web traffic by country

6.7K monthly visits
across markets

🇺🇸 United States71.6%

🇮🇳 India22.4%

🇨🇦 Canada7.5%

Top 3 markets shown

Market sentiment

What the market is saying about Puma Biotechnology

An AI-synthesized read of the highest-engagement posts about Puma Biotechnology on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Puma Biotechnology on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles